NEW YORK (GenomeWeb) – Israeli biotech firm Can-Fite BioPharma announced today an agreement with Smart Assays to develop a biomarker blood test kits for the A3 adenosine receptor (A3AR).

Molecular biology labs would be able to use Can-Fite's A3AR biomarker kit to identify a patient's response to the firm's drugs. A3AR is present in high concentrations in inflammatory cells and cancer cells, and Can-Fite's drugs target and bind to A3AR, causing cell apoptosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.